Original article| Volume 11, ISSUE 4, P874-881, July 2015

Download started.


The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity

Published:December 16, 2014DOI:



      Saline-filled intragastric balloon devices are reversible endoscopic devices designed to occupy stomach volume and reduce food intake. Objective: To evaluate the safety and effectiveness of a dual balloon system plus diet and exercise in the treatment of obesity compared to diet and exercise alone. Setting: Academic and community practice, United States.


      Participants (n = 326) with body mass index (BMI) 30–40 kg/m2 were randomized to endoscopic DBS treatment plus diet and exercise (DUO, n = 187) or sham endoscopy plus diet and exercise alone (DIET, n = 139). Co-primary endpoints were a between-group comparison of percent excess weight loss (%EWL) and DUO subject responder rate, both at 24 weeks. Thereafter DUO patients had the DBS retrieved followed by 24 additional weeks of counseling; DIET patients were offered DBS treatment.


      Mean BMI was 35.4. Both primary endpoints were met. DUO weight loss was over twice that of DIET. DUO patients had significantly greater %EWL at 24 weeks (25.1% intent-to-treat (ITT), 27.9% completed cases (CC, n = 167) compared with DIET patients (11.3% ITT, P = .004, 12.3% CC, n = 126). DUO patients significantly exceeded a 35% response rate (49.1% ITT, P<.001, 54.5% CC) for weight loss dichotomized at 25%EWL. Accommodative symptoms abated rapidly with support and medication. Balloon deflation occurred in 6% without migrations. Early retrieval for nonulcer intolerance occurred in 9%. Gastric ulcers were observed; a minor device change led to significantly reduced ulcer size and frequency (10%).


      The DBS was significantly more effective than diet and exercise in causing weight loss with a low adverse event profile.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dumonceau J.M.
        Evidence-based review of the BioEnterics intragastric balloon for weight loss.
        Obes Surg. 2008; 18: 1611-1617
        • Imaz I.
        • Martinez-Cervell C.
        • Garcia-Alvarez E.E.
        • Sendra-Gutierrez J.M.
        • Gonzalez-Enriquez J.
        Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis.
        Obes Surg. 2008; 18: 841-846
        • Ponce J.
        • Quebbeman B.B.
        • Patterson E.J.
        Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity.
        Surg Obes Relat Dis. 2012; 9: 290-295
        • Genco A.
        • Cipriano M.
        • Bacci V.
        • et al.
        BioEnterics Intragastric Balloon (BIB): a short term, double blind, randomized, controlled crossover study on weight reduction in morbidly obese patients.
        Int J Obes. 2006; 30: 129-133
        • Martinez Brocca M.A.
        • Belda O.
        • Parejo J.
        • et al.
        Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity.
        Obes Surg. 2007; 17: 649-657
        • Mathus-Vliegen E.M.
        • de Groot G.H.
        Fasting and meal-induced CCK and PP secretion following intragastric balloon treatment for obesity.
        Obes Surg. 2013; 23: 622-633
        • Mathus-Vliegen E.M.
        • Tytgat G.N.
        Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up.
        Gastrointest Endosc. 2005; 61: 19-27
        • Kotzampassi K.
        • Grosomanidis V.
        • Papakostas P.
        • Penna S.
        • Eleftheriadis E.
        500 Intragastric Balloons: What Happens 5 Years Thereafter?.
        Obes Surg. 2012; 22: 896-903
        • Lopez-Nava G.
        • Rubio M.A.
        • Prados S.
        • et al.
        BioEnterics® intragastric balloon (BIB®). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons.
        Obes Surg. 2010; 21: 5-9
        • Mui W.L.
        • Ng E.K.
        • Tsung B.Y.
        • Lam C.H.
        • Yung M.Y.
        Impact on obesity-related illnesses and quality of life following intragastric balloon.
        Obes Surg. 2010; 20: 1128-1132
        • Genco A.
        • Lopez-Nava G.
        • Wahlen C.
        • et al.
        Multi-centre European experience with intragastric balloon in overweight populations: 13 years of experience.
        Obes Surg. 2013; 23: 515-521
        • Dumonceau J.M.
        • Francois E.
        • Hittelet A.
        • Mehdi A.I.
        • Barea M.
        • Deviere J.
        Single vs repeated treatment with the intragastric balloon: a 5-year weight loss study.
        Obes Surg. 2010; 20: 692-697
        • Genco A.
        • Cirpriano M.
        • Bacci V.
        • et al.
        Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients.
        Obes Surg. 2010; 20: 1496-1500
        • Peker Y.
        • Coskun H.
        • Bozkurt S.
        • Cin N.
        • Atak T.
        • Genc H.
        Comparison of results of laparoscopic gastric banding and consecutive intragastric balloon application at 18 months: a clinical prospective study.
        J Laparoendosc Adv Surg Tech A. 2011; 21: 471-475
        • Coskun H.
        • Bostanci O.
        Assessment of the application of the intragastric balloon together with sibutramine: a prospective clinical study.
        Obes Surg. 2010; 20: 1117-1120
        • Farina M.G.
        • Baratta R.
        • Nigro A.
        • et al.
        Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity.
        Obes Surg. 2012; 22: 565-571
        • Al-Momen A.
        • El-Mogy I.
        Intragastric balloon for obesity: a retrospective evaluation of tolerance and efficacy.
        Obes Surg. 2005; 15: 101-105
        • de la Riva S.
        • Munoz-Navas M.
        • Rodriguez-Lago I.
        • Silva C.
        Small-bowel migration: a possible complication of adjustable intragastric balloons.
        Endoscopy. 2012; 44: E224
        • Doldi S.B.
        • Micheletto G.
        • Di Prisco F.
        • Zappa M.A.
        • Lattuada E.
        • Reitano M.
        Intragastric balloon in obese patients.
        Obes Surg. 2000; 10: 578-581
        • Genco A.
        • Bruni T.
        • Doldi S.B.
        • et al.
        BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients.
        Obes Surg. 2005; 15: 1161-1164
        • Nijhof H.W.
        • Steenvoorde P.
        • Tollenaar R.A.
        Perforation of the esophagus caused by the insertion of an intragastric balloon for the treatment of obesity.
        Obes Surg. 2006; 16: 667-670
        • Roman S.
        • Napoleon B.
        • Mion F.
        • et al.
        Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy.
        Obes Surg. 2004; 14: 539-544
        • The Practical Guide
        Identification, Evaluation, and Treatment of Overweight and Obesity in Adults.
        National Institute of Health, NIH Publication Number 00-4084. October 2000;
        • James K.E.
        • Bloch D.A.
        • Lee K.K.
        • Kraemer H.C.
        • Fuller R.K.
        An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation--a VA cooperative study.
        Stat Med. 1996; 15: 1421-1434
        • Bang H.
        • Ni L.
        • Davis C.E.
        Assessment of blinding in clinical trials.
        Control Clin Trials. 2004; 25: 143-156
        • Nguyen N.
        • Champion J.K.
        • Ponce J.
        • et al.
        A review of unmet needs in obesity management.
        Obes Surg. 2012; 22: 956-966
        • Boers M.
        • Tangelder M.J.
        • van Ingen H.
        • Fort J.G.
        • Goldstein J.L.
        The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials.
        Ann Rheum Dis. 2007; 66: 417-418
        • Chan F.K.
        • Lanas A.
        • Scheiman J.
        • Berger M.F.
        • Nguyen H.
        • Goldstein J.L.
        Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
        Lancet. 2010; 376: 173-179
        • Goldstein J.L.
        • Chan F.K.
        • Lanas A.
        • et al.
        Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
        Aliment Pharmacol Ther. 2011; 34: 70808-70816
        • Lopez-Nava G.
        • Bautista-Castano I.
        • Jimenez-Banos A.
        • de Grado Manchado T.
        Fernandez-Corbelle J. A prospective evaluation of a new dual intragastric balloon.
        Obes Surg. 2014; 24: 1131